Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome

Teri J. Mauch, Michael R. Chladek, Spero Cataland, Shruti Chaturvedi, Bradley P. Dixon, Katherine Garlo, Christoph Gasteyger, Anuja Java, Jorge Leguizamo, Lucy Lloyd-Price, Tan P. Pham, Tara Symonds, Ioannis Tomazos, Yan Wang

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Treatment preference and quality of life impact: ravulizumab vs eculizumab for atypical hemolytic uremic syndrome'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences